| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T286 |
0-203 |
Sentence |
denotes |
At the time of writing, and to the best of our knowledge, there are three Food and Drug Administration (FDA)-approved drugs derived from the FBDD approach [221], and over 30 are in clinical trials [222]. |
| T287 |
204-279 |
Sentence |
denotes |
The first marketed drug derived via the FBDD approach is vemurafenib [223]. |
| T288 |
280-467 |
Sentence |
denotes |
Vemurafenib is also the first drug approved for treatment of BRAF-mutant cancer [224], and is reported to exhibit significant clinical benefit for patients with metastatic melanoma [224]. |
| T289 |
468-686 |
Sentence |
denotes |
Venetoclax, a common drug used to treat patients with chronic lymphocytic leukemia [225], is considered the second drug to be discovered using the FBDD approach [221], and ribociclib, a CDK4 inhibitor, the third [221]. |
| T290 |
687-830 |
Sentence |
denotes |
The names, structures, targets/applications, and clinical status of vemurafenib, venetoclax, ribociclib, and other drugs are listed in Table 2. |
